Clinical Study

Oral Curcumin (Meriva) Is Effective as an Adjuvant Treatment and Is Able to Reduce IL-22 Serum Levels in Patients with Psoriasis Vulgaris

Figure 2

Median PASI values [25°–75° percentile] at baseline (T0) and after 12 weeks (T12) in patients treated with topical methylprednisolone + Meriva (curcumin) or with topical methylprednisolone + placebo (placebo). .